Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

<div>Dynamics of brain metastases on lorlatinib. Axial brain CT showing brain metastases (white arrows) after lorlatinib dose reduction (a). Axial brain MRI (T1 with contrast) performed two months after resuming full dose lorlatinib showing complete resolution of all brain lesions (b).</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC 